Quick answers
- What is Neupogen?
- Neupogen is a brand name of Filgrastim, a prescription medicine. The FDA NDC Directory lists 4 Neupogen products in 4 strengths and forms.
- Who makes Neupogen?
- Amgen holds the FDA application for Neupogen (BLA103353, approved February 20, 1991).
- Is there a generic or store brand of Neupogen?
- Yes. The FDA NDC Directory lists 16 other products with the same active ingredients, strength and form as a Neupogen product. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Neupogen?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 2 Neupogen strengths and forms (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Neupogen been recalled?
- FDA enforcement reports list 2 recalls of Neupogen products; the newest started February 27, 2025. A recall usually concerns specific lots, not every product.
What Neupogen is
Each Neupogen product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Filgrastim · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| filgrastim 300 ug/0.5 mL injection, solution (intravenous, subcutaneous) | Neupogen | 5 products, 5 companies | DailyMed |
| filgrastim 300 ug/mL injection, solution (intravenous, subcutaneous) | Neupogen | 3 products, 3 companies | DailyMed |
| filgrastim 480 ug/0.8 mL injection, solution (intravenous, subcutaneous) | Neupogen | 5 products, 5 companies | DailyMed |
| filgrastim 480 ug/1.6 mL injection, solution (intravenous, subcutaneous) | Neupogen | 3 products, 3 companies | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Filgrastim →
FDA approval
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| BLA103353 | Amgen | February 20, 1991 | 4 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| filgrastim 300 ug/0.5 mL injection, solution | Brand: Neupogen | $650.05 per mL |
| filgrastim 300 ug/mL injection, solution | Brand: Neupogen | $304.09 per mL |
NADAC list of November 4, 2026; these prices took effect between August 19, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Neupogen
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Neupogen products.
- Amgen, Inc4 products
Recalls
From FDA enforcement reports, matched by the product’s NDC code or label. A recall usually covers specific lots: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
February 27, 2025 · Class II · Ongoing · D-0285-2025
Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.
Neupogen (filgrastim) For Injection, 300mcg/1 mL, 1 mL Single Dose Vials, Rx Only, For Subcutaneous or Intravenous Use Only, Sterile Solution - No Preservative, Amgen Inc., Thousand Oaks, CA 91320, NDC 55513-530-01 (vial — Amgen, Inc.
-
February 27, 2025 · Class II · Ongoing · D-0286-2025
Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.
Neupogen (filgrastim) For Injection, 480 mcg/1.6 mL (300 mcg/1 mL), 1.6 mL single Dose Vial, Rx Only, For Subcutaneous or Intravenous Use Only, Sterile Solution - No Preservative, Amgen Inc. Thousand Oaks, CA 91320, NDC — Amgen, Inc.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.